PRIMARY SCLEROSING CHOLANGITIS MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Primary Sclerosing Cholangitis Market - Overview Global Primary Sclerosing Cholangitis Market, by Drug (BT1023, GS-9674, NGM282, OCA, LUM001, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) has potential pipeline products and is estimated to reach US$ 140.4 Mn by 2023. For instance, the discovery and development of siRNA (small interfering RNA) therapeutics by Sirnaomics, Inc., with dual-target properties and polypeptide nanoparticle (PNP)-enhanced delivery that directly controls the fibrotic and inflammatory activity is expected to have wide applications in many inflammatory and fibrotic diseases. The support from the public and private organizations such as PSC Support Organization and National Organization for Rare Disorders serves as the hub of rare disease community, providing assistance programs for patients and advancing clinical trials by granting funds for advanced research programs. The UK PSC Support Organization granted US$ 20,000 to the University of Birmingham for supporting the research and investigation of Vascular Adhesion Protein (VAP-1) in primary sclerosing cholangitis (PSC). Also, in 2017, the Falk Foundation funded a European multi-center phase II study led by the Medical University of Vienna in collaboration with the Medical University of Graz and the Medical University of Hannover, to treat primary sclerosing cholangitis. Browse Research Reports: https://www.coherentmarketinsights.com/market-insight/primarysclerosing-cholangitis-market-1960 © Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Orphan drug designation granted by regulatory agencies such as the Food and Drug Administration (FDA) and European Medicine Agency (EMA) for the treatment of PSC enables manufacturers to accelerate the drug development process for providing new drug treatments to patients in need. For instance, in 2017, Conatus Pharmaceuticals Inc. was granted orphan designation to IDN-7314 by the FDA and EMA. The drug completed two successful pre-clinical trials, of which the second one was completed in 2017. Also, pharmaceuticals companies are focusing on mergers and acquisitions to accelerate the development of new treatment options to address the unmet needs of patients suffering from rare diseases by advancing the therapies into clinical trials. For instance, in 2015, Gilead Sciences, Inc. acquired Phenex Pharmaceuticals AG, to gain access to Phenex’s Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including PSC and nonalcoholic steatohepatitis (NASH). Also, in February 2018, Intercept Pharmaceuticals, Inc. collaborated with Sumitomo Dainippon Pharma Co. Ltd., to develop and commercialize Obeticholic Acid (OCA) for chronic liver disease in Japan, China, and Korea. In 2014, Shire acquired Lumena Pharmaceuticals, to gain access to its late-stage rare disease pipeline assets indicated for gastrointestinal conditions- LUM001 and LUM002, thus providing potential treatment options to patients with rare cholestatic liver disease and adding products to its rare disease portfolio. Request a Sample copy of this reports: https://www.coherentmarketinsights.com/insight/request-sample/1960 © Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Key Takeaways of the Primary Sclerosing Cholangitis Market: According to the Research Institute of Radiological Science, 2016, the prevalence of PSC is higher in Northern Europe and the U.S. around 10 per 100,000 population, while it is far less common in Southern Europe and Asia Requirement of providing affordable treatment, owing to high costs associated with liver transplantation coupled with increasing risk factors resulting in the development of serious disorders are factors that are expected to bolster market growth in the near future. Some of the major players operating in the global primary sclerosing cholangitis market include Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd. Also, in 2016, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for BTT1023 drug candidate developed by Acorda Therapeutics, which is in Phase 2 clinical trials currently.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1960 © Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele.
SERVICES INDUSTRY ANALYSIS
CUSTOMIZED RESEARCH
SYNDICATED RESEARCH
MARKET INTELLIGENCE SERVICES
CONSULT STUDIES
COUNTRY SPECIFIC STUDIES
© Coherent market Insights. All Rights Reserved
ABOUT CMI SECTOR COVERAGE
BIOTECHNOLOGY
CLINICAL DIAGNOSTIC
HEALTHCARE IT
MEDICAL DEVICES
MEDICAL IMAGING
PHARMACEUTICAL
OUR CLIENTS
Global Leading Equipment and System Manufacturers Marketing Consultancies and the Advertising Industry
Component Providers and System Integrators
Private and Government organization
Distributors, Retailors and Value Added Resellers
Outsourcing Companies
Healthcare IT Solutions Developers
Universities and Business Schools.
© Coherent market Insights. All Rights Reserved
KEY STATS
RESEARCH SOLUTIONS
100+
FEASIBILITY STUDIES
Insights Published Per Year
GLOBAL REPORTS
150+
Consulting Projects Till Date
COUNTRY ANALYSIS CONSULT PROJECTS
125+
Clients Worldwide Per Year
110+
SURVEY RESEARCH
EXCEL FORECAST DATABASE
CUSTOMIZED SOLUTIONS
COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS
Analysts and Contract Consultants
Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved
THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702
© Coherent market Insights. All Rights Reserved